By Justin Petrone

NanoString Technologies has licensed a gene-expression signature from a coalition of university researchers that can be used to classify different breast cancer subtypes, according to a company official.

NanoString CEO Brad Gray told BioArray News this week that the firm intends to have the breast cancer intrinsic subtyping assay on the US market for clinical use in two years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.